The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study
Abstract
Objective: Patients with rheumatoid arthritis (RA) who experience treatment failure with one anti–tumor necrosis factor (anti‐TNF) agent, due to either inefficacy or toxicity, are frequently switched to a second anti‐TNF agent, although the benefits of switching are unknown. The present study was undertaken to compare drug continuation rates between the first course and second course of anti‐TNF therapy. Methods: The study involved a prospective cohort of RA patients from a UK national register of new anti‐TNF treatment starts (n = 6,739; 876 starting adalimumab, 2,826 starting etanercept, and starting 3,037 infliximab). Over a mean 15 months of followup, 841 patients stopped taking the first drug due to inefficacy and 1,023 stopped the first drug due to toxicity, of whom 503 and 353, respectively, were switched to a second anti‐TNF agent. Kaplan‐Meier survival curves were plotted to determine continuation rates for each course, and Cox regression was used to compare each course for the risk of stopping and the reason for stopping (inefficacy or toxicity). Results: Overall, 73% of patients who switched to a second anti‐TNF agent remained on the new therapy by the end of followup. First drug discontinuation due to inefficacy was associated with an increased rate of second drug discontinuation due to inefficacy (hazard ratio [HR] 2.7, 95% confidence interval [95% CI] 2.1–3.4) but not toxicity (HR 1.1, 95% CI 0.9–1.5). Similarly, first drug discontinuation due to toxicity was associated with an increased rate of second drug discontinuation due to toxicity (HR 2.3, 95% CI 1.9–2.9) but not inefficacy (HR 1.2, 95% CI 0.8–1.6). Conclusion: RA patients who are switched to a second anti‐TNF drug have high rates of continuation, although among those who must discontinue treatment, the reasons for stopping a second drug are related to the reasons for stopping the first drug. This large data set from the UK provides the first estimates of the magnitude of these effects in patients with long‐standing severe RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Klareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Mola, E. M., Pavelka, K., Sany, J., Settas, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15640-7 · Cited by 1,751
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MACFARLANE, J. D., Antoni, C., Leeb, B. F., Elliott, M. J., Woody, J. N., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w · Cited by 1,627
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Van den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.-Y., Shealy, D., & Wagner, C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.418 · Cited by 672
KIRWAN, J. R., & REEBACK, J. S. (1986) · Rheumatology · doi:10.1093/rheumatology/25.2.206 · Cited by 488
Ledingham, J., Deighton, C., & on behalf of the British Society for Rheumatology Standards, G. A. A. W. G. (2005) · Rheumatology · doi:10.1093/rheumatology/keh464 · Cited by 331
Catrina, A. I., Trollmo, C., af Klint, E., Engstrom, M., Lampa, J., Hermansson, Y., Klareskog, L., & Ulfgren, A. K. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20764 · Cited by 255
Geborek, P., Crnkic, M., Petersson, I. F., & Saxne, T. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.9.793 · Cited by 253
British Society for Rheumatology Biologics Register
Silman, A. J., Symmons, D. P. M., Scott, D. G. I., & Griffiths, I. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.suppl_2.ii28 · Cited by 248
Self-citationvan Vollenhoven, R., Harju, A., Brannemark, S., & Klareskog, L. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.009589 · Cited by 221
Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles
Anderson, P. J. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.01.005 · Cited by 202
Grom, A. A., Murray, K. J., Luyrink, L., Emery, H., Passo, M. H., Glass, D. N., Bowlin, T., & Edwards, C. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391013 · Cited by 164
Hyrich, K. L., Symmons, D. P. M., Watson, K. D., Silman, A. J., & British Society for Rheumatology Biologics Register (2006) · Arthritis & Rheumatism · doi:10.1002/art.21830 · Cited by 144
Self-citationThe efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
Hansen, K. E., Hildebrand, J. P., Genovese, M. C., Cush, J. J., Patel, S. R., Cooley, D. A., Cohen, S. B., Gangnon, R. E., & Schiff, M. H. (2004) · PubMed · Cited by 117
Discovery of TNF-α as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies
Feldmann, M., & Maini, R. N. (2002) · Joint Bone Spine · doi:10.1016/s1297-319x(01)00335-9 · Cited by 84
Finckh, A., Simard, J. F., Duryea, J., Liang, M. H., Huang, J., Daneel, S., Forster, A., Gabay, C., & Guerne, P. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21491 · Cited by 78
Lymphotoxin β–mediated stimulation of synoviocytes in rheumatoid arthritis
Braun, A. B., Takemura, S., Vallejo, A. N., Goronzy, J. J., & Weyand, C. M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20356 · Cited by 60
Cited by
Emery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., & Kremer, J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092932 · Cited by 1,104
Keystone, E., Heijde, D. V. D., Mason, D., Landewé, R., Vollenhoven, R. V., Combe, B., Emery, P., Strand, V., Mease, P., Desai, C., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23964 · Cited by 576
Smolen, J. S., Kay, J., Doyle, M. K., Landewé, R., Matteson, E. L., Wollenhaupt, J., Gaylis, N., Murphy, F. T., Neal, J. S., Zhou, Y., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60506-7 · Cited by 526
Smolen, J. S., Landewé, R., Breedveld, F. C., Dougados, M., Emery, P., Gaujoux-Viala, C., Gorter, S., Knevel, R., Nam, J., Schoels, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.126532 · Cited by 409
Radstake, T. R. D. J., Svenson, M., Eijsbouts, A. M., van den Hoogen, F. H. J., Enevold, C., van Riel, P. L. C. M., & Bendtzen, K. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092833 · Cited by 377
Metadata
- Authors
- Hyrich, K. L., Lunt, M., Watson, K. D., Symmons, D. P. M., Silman, A. J., & British Society for Rheumatology Biologics Register
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2007-01
- Volume
- 56
- Issue
- 1
- Pages
- 13-20
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2014709373
- Cited by
- 401
- References
- 22
- FWCI
- 20.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.